Abstract
Background:
Keloids represent a therapeutic challenge due to their high recurrence rates and resistance to conventional treatment. Surgical excision, often considered a first-line treatment, is associated with recurrence rates exceeding 50% even when combined with adjuvant therapies. Similarly, intralesional corticosteroid injections, another widely used modality, provide variable results, with recurrence rates ranging from 9% to 50% and frequent complications, including hypopigmentation, atrophy, and pain. These outcomes underscore the need for innovative and more effective treatments.